Drug recalls (page 5)

748 recalls.

• Niacin Extended-release Tablets recall (Lannett Company Inc.)
  DrugClass IIReported June 10, 2026 · Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.
• TopCare health recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• TopCare health recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• EQUALINE ultra strength recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• EQUALINE extra strength recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• GOODSENSE Ultra Strength recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• GOODSENSE Extra Strength recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• H.E.B Extra Strength Calcium Carbonate Antacid Tablets recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• HyVee recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• HyVee recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• Harris Teeter recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• FAMILY WELLNESS recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• FAMILY WELLNESS recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• DISCOUNT drug mart recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• CAREone recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• CAREone recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• MARKET BASKET ANTACID Calcium Carbonate 1000 mg recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• 24/7 life BY 7-ELEVEN recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• Extra strength Antacid Calcium Carbonate 750 mg recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• Good Neighbor Pharmacy recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• Good Neighbor Pharmacy recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• HALEON CALCIUM CARBONATE TUMS ANTACID recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• HALEON CALCIUM CARBONATE TUMS ANTACID recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• KIRKLAND Signature recall (Guardian Drug Co. Inc.)
  DrugClass IIReported June 10, 2026 · Presence of foreign substance: small metallic particles in chewable tablets.
• Amlodipine and Olmesartan Medoxomil Tablets recall (Ascend Laboratories, LLC)
  DrugClass IIReported June 10, 2026 · Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
• Duloxetine DR Capsules recall (Asclemed USA Inc.)
  DrugClass IIReported June 10, 2026 · CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.
• Lidocaine HCl Injection USP recall (Spectra Medical Devices, Llc)
  DrugClass IIReported June 10, 2026 · Lack of Assurance of Sterility
• Lidocaine HCl Injection recall (Eugia US LLC)
  DrugClass IIIReported June 10, 2026 · Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan
• PRED MILD recall (AbbVie Inc.)
  DrugClass IIIReported June 3, 2026 · Failed Stability Specifications
• Nicotine Transdermal System Patch recall (AVEVA Drug Delivery Systems, Inc.)
  DrugClass IIIReported June 3, 2026 · Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of...
• MG217 Multi-Symptom Treatment Cream & Skin Protectant recall (Wisconsin Pharmacal Company)
  DrugClass IReported May 27, 2026 · Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
• Vitamin B-Complex recall (Safecor Health, LLC)
  DrugClass IIReported May 27, 2026 · Presence of a Foreign Substance; black particles observed in liquid
• fentaNYL Citrate recall (IntegraDose Compounding Services LLC)
  DrugClass IIReported May 27, 2026 · Subpotent Drug
• cimzia recall (UCB Biosciences Inc.)
  DrugClass IIReported May 27, 2026 · Lack of Assurance of Sterility
• Erythromycin Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported May 27, 2026 · CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
• Erythromycin Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported May 27, 2026 · CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
• Estradiol Gel recall (ANI Pharmaceuticals, Inc.)
  DrugClass IIReported May 27, 2026 · Defective Container; packets were found to be either empty or partially full.
• Gas-X recall (Haleon US Holdings LLC)
  DrugClass IIReported May 27, 2026 · Labeling: Not Elsewhere Classified- Incomplete inactive ingredient information on the carton labeling.
• Liraglutide Injection recall (Lupin Pharmaceuticals Inc.)
  DrugClass IIReported May 27, 2026 · Presence of particulate matter: a white thread-like structure in the cartridge
• Busulfan Injection recall (Sagent Pharmaceuticals)
  DrugClass IIIReported May 27, 2026 · Failed Impurities/Degradation Specifications
• Atomoxetine Capsules HCL recall (Safecor Health, LLC)
  DrugClass IIReported May 27, 2026 · Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.
• Primidone Tablets recall (Amerisource Health Services LLC)
  DrugClass IIIReported May 27, 2026 · Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
• Primidone Tablets recall (Amerisource Health Services LLC)
  DrugClass IIIReported May 27, 2026 · Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
• Primidone Tablets recall (Golden State Medical Supply Inc.)
  DrugClass IIIReported May 27, 2026 · Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
• Primidone Tablets recall (Golden State Medical Supply Inc.)
  DrugClass IIIReported May 27, 2026 · Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
• Primidone Tablets USP recall (Lannett Company Inc.)
  DrugClass IIIReported May 27, 2026 · Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
• Ascend Laboratories recall (Ascend Laboratories, LLC)
  DrugClass IIReported May 20, 2026 · Failed Dissolution Specifications
• Buprenorphine Hydrochloride recall (ENDO USA, Inc.)
  DrugClass IIReported May 20, 2026 · Crystallization; identified as Buprenorphine free base
• Oasis Tears PF recall (Oasis Medical, Inc.)
  DrugClass IIReported May 20, 2026 · Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of...
• Lactated Ringer's Injection USP recall (B BRAUN MEDICAL INC)
  DrugClass IReported May 13, 2026 · Presence of Particulate Matter.
• TPN bag recall (Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles)
  DrugClass IIReported May 13, 2026 · Incorrect Product Formulation: product did not contain insulin as listed in the label.
• NAPROXEN ORAL SUSPENSION recall (Acella Pharmaceuticals, LLC)
  DrugClass IIReported May 13, 2026 · Chemical contamination; presence of lead and lithium above specification
• Duloxetine Delayed-Release Capsules USP recall (Breckenridge Pharmaceutical, Inc.)
  DrugClass IIReported May 13, 2026 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
• Enalapril Maleate Tablets recall (JB Chemicals and Pharmaceuticals Ltd)
  DrugClass IIReported May 13, 2026 · Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
• Octreotide Acetate for Injectable Suspension recall (Teva Pharmaceuticals USA, Inc)
  DrugClass IIReported May 13, 2026 · Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract...
• BD PurPrep recall (CareFusion 213, LLC)
  DrugClass IIReported May 13, 2026 · Lack of assurance of Sterility: potential product contamination
• BD PurPrep recall (CareFusion 213, LLC)
  DrugClass IIReported May 13, 2026 · Lack of assurance of Sterility: potential product contamination
• Duloxetine Delayed-Release Capsules recall (Ajanta Pharma Ltd.)
  DrugClass IIReported May 13, 2026 · CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability...
• Duloxetine Delayed-Release Capsules recall (Ajanta Pharma Ltd.)
  DrugClass IIReported May 13, 2026 · CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability...
• Duloxetine Delayed-Release Capsules recall (Ajanta Pharma Ltd.)
  DrugClass IIReported May 13, 2026 · CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability...
• DELFLEX recall (Fresenius Medical Care Holdings, Inc.)
  DrugClass IIReported May 13, 2026 · Lack of Assurance of Sterility: Potential leaks from perforations in bags.
• DELFLEX recall (Fresenius Medical Care Holdings, Inc.)
  DrugClass IIReported May 13, 2026 · Lack of Assurance of Sterility: Potential leaks from perforations in bags.
• busPIRone Hydrochloride Tablets recall (Unichem Pharmaceuticals USA Inc.)
  DrugClass IIIReported May 13, 2026 · Subpotent drug
• Alendronate Sodium Oral Solution recall (Hikma Pharmaceuticals USA INC)
  DrugClass IIReported May 6, 2026 · This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.
• Lidocaine Wound Gel recall (Water-Jel Technologies, LLC)
  DrugClass IIIReported May 6, 2026 · Failed PH Specifications
• fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• Ketamine Hydrochloride Injectable Solution recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• fentaNYL Citrate Injectable Solution recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• fentaNYL Citrate Injectable Solution recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• Phenylephrine Hydrochloride Injectable Solution recall (Wells Pharma of Houston LLC)
  DrugClass IIReported May 6, 2026 · cGMP deviations.
• Similasan recall (Thea Pharma, Inc.)
  DrugClass IIReported May 6, 2026 · Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.
• iVIZIA recall (Thea Pharma, Inc.)
  DrugClass IIReported May 6, 2026 · Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.
• Optase Dry Eye Intense Drops recall (SCOPE HEALTH)
  DrugClass IIReported May 6, 2026 · Lack of Assurance of Sterility
• Levocarnitine Injection recall (American Regent, Inc.)
  DrugClass IIIReported May 6, 2026 · Labeling: Missing Label
• GenTeal Tears recall (Alcon Research LLC)
  DrugClass IIReported May 6, 2026 · Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
• Systane recall (Alcon Research LLC)
  DrugClass IIReported May 6, 2026 · Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
• Claravis recall (Teva Pharmaceuticals USA, Inc)
  DrugClass IIReported April 29, 2026 · Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
• LACTATED RINGER'S IRRIGATION recall (B BRAUN MEDICAL INC)
  DrugClass IIReported April 29, 2026 · Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
• 0.9 % SODIUM CHLORIDE IRRIGATION recall (B BRAUN MEDICAL INC)
  DrugClass IIReported April 29, 2026 · Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
• DEXTROSE INJECTION USP recall (B BRAUN MEDICAL INC)
  DrugClass IIReported April 29, 2026 · Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
• Sterile Water for Injection USP recall (B BRAUN MEDICAL INC)
  DrugClass IIReported April 29, 2026 · Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
• Omega-3-Acid recall (The Harvard Drug Group LLC)
  DrugClass IIReported April 29, 2026 · Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.
• Premier recall (Premier Dental Products Co)
  DrugClass IIIReported April 29, 2026 · Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14)....
• FRESHKOTE LUBRICANT EYEDROPS recall (Harrow Eye LLC)
  DrugClass IIReported April 29, 2026 · Lack of Assurance of Sterility
• Furosemide Tablets recall (Leading Pharma, LLC)
  DrugClass IIReported April 29, 2026 · CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
• Pantoprazole Sodium recall (Hetero Labs Limited (Unit V))
  DrugClass IIReported April 29, 2026 · Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."
• Lidocaine HCl Injection recall (Huons Co., Ltd.)
  DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility
• 0.9% Sodium Chloride Injection recall (Huons Co., Ltd.)
  DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility
• Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection recall (Huons Co., Ltd.)
  DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility
• Lidocaine HCl injection recall (Huons Co., Ltd.)
  DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility
• Desmopressin Nasal Spray recall (Apotex Corp.)
  DrugClass IIReported April 22, 2026 · Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.
• Magnesium Chloride recall (Avantor Performance Materials LLC)
  DrugClass IIIReported April 22, 2026 · Subpotent drug
• Blemish Spot Treatment recall (Island Kinetics, Inc. d.b.a. CoValence Laboratories)
  DrugClass IIReported April 22, 2026 · Failed Stability Specifications
• Memantine Hydrochloride Extended-Release recall (The Harvard Drug Group LLC)
  DrugClass IIReported April 22, 2026 · Failed Dissolution Specifications
• EPINEPHRINE Injection recall (International Medication Systems Ltd.)
  DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility
• Essential Calming Skin Gel recall (Island Kinetics, Inc. d.b.a. CoValence Laboratories)
  DrugClass IIIReported April 22, 2026 · Subpotent Drug
• Skin Rehab recall (Island Kinetics, Inc. d.b.a. CoValence Laboratories)
  DrugClass IIIReported April 22, 2026 · Subpotent Drug
• Remedy Gel recall (Island Kinetics, Inc. d.b.a. CoValence Laboratories)
  DrugClass IIIReported April 22, 2026 · Subpotent Drug

← NewerOlder →